Mesothelioma

New Survey Reveals Present-Day Risks of Asbestos Exposure in America - 38% in High-Risk Jobs, 47% Vulnerable through Second-Hand Exposure

Retrieved on: 
Thursday, April 4, 2024
Law, Asbestos, Risk, Education, Lung, Public, PLLC, Cancer, Mesothelioma, EPA, Sickness, Gen

These findings, released today, underscore the urgent necessity for Asbestos Cancer Risk Awareness and routine testing.

Key Points: 
  • These findings, released today, underscore the urgent necessity for Asbestos Cancer Risk Awareness and routine testing.
  • They emphasize the crucial importance of proactive measures to mitigate the pervasive risks associated with asbestos exposure in the United States.
  • Awareness about the risks of asbestos exposure appears to be widespread, with 45% of respondents acknowledging the potential dangers.
  • For more information on asbestos risks and testing, including an infographic, podcast, and video, visit this page .

OncoC4 Expands Scientific Advisory Board with Appointment of Heather A. Wakelee, MD, FASCO

Retrieved on: 
Tuesday, April 2, 2024
Lung cancer, Internal medicine, Stanford Cancer Institute, Entrepreneurship, Princeton University, Immunotherapy, Oncology, International Association, Research, Cancer, Doctor of Philosophy, MD, Mesothelioma, CD24, MacArthur Fellows Program, Johns Hopkins University, Principal investigator, SAB, Division, Stanford University, CSO, Thymoma, Pharmaceutical industry

“We are honored to welcome Heather to the OncoC4 SAB, an international expert with decades of leadership experience in the treatment of lung cancer,” said Yang Liu, PhD, Co-Founder, CEO and CSO of OncoC4.

Key Points: 
  • “We are honored to welcome Heather to the OncoC4 SAB, an international expert with decades of leadership experience in the treatment of lung cancer,” said Yang Liu, PhD, Co-Founder, CEO and CSO of OncoC4.
  • By leveraging universal pathways, OncoC4 has the potential to change the treatment paradigm for many common and aggressive cancers with high unmet needs.
  • Currently she serves as Deputy Director of the Stanford Cancer Institute and is the Division Chief of Medical Oncology.
  • She is the Principal Investigator on numerous clinical trials and has held advisory board roles with multiple international pharmaceutical companies.

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 28, 2024
Ovarian cancer, SLS, Survival, Lymphoma, Fast track (FDA), PTCL, National Cancer Institute, CMC, Clinical trial, Committee, Research, NCI, European School, Bone marrow, AML, GPS, Pembrolizumab, Doctor of Science, Nivolumab, Safety, MRD, CDK9, BLA, Food, CR2, Zanubrutinib, Mesothelioma, BIW, MD, Completeness, WT1, FDA, DLBCL, IDMC, Therapeutic index, Type, Fast Track, Biomarker, BTK, Pharmaceutical industry

The SLS009 aza-ven treatment was well-tolerated and evoked anti-leukemic effects in 67% of patients across all levels dosed.

Key Points: 
  • The SLS009 aza-ven treatment was well-tolerated and evoked anti-leukemic effects in 67% of patients across all levels dosed.
  • The first patient who achieved a complete response continues on the study and remains leukemia-free 9 months post-enrollment.
  • The net proceeds from the offering strengthen the Company’s financial position and will be used for research and development activities, working capital, and general corporate purposes.
  • Cash Position: As of December 31, 2023, cash and cash equivalents totaled approximately $2.5 million.

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Biopsy, NSCLC, Entrepreneurship, Carcinoma, DLL4, Patient, Neoplasm, PET, Merck, G&A, Doctor of Philosophy, MD, Insurance, IND, Mesothelioma, Research and development, CD137, Therapy, Paclitaxel, BTC, CRC, Melanoma, Stage 2, PD-L1, FDA, SCLC, PD-1, Pharmaceutical industry

Ended 2023 with $152 million in cash and marketable securities, which is expected to provide cash runway into mid-year 2026.

Key Points: 
  • Ended 2023 with $152 million in cash and marketable securities, which is expected to provide cash runway into mid-year 2026.
  • BOSTON, March 21, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported full 2023 financial results and provided business update.
  • The increase was primarily attributable to higher stock compensation expense of $1.0 million offset by lower insurance costs of $0.3 million.
  • During 2023, the Company decreased its cash position by $34.1 million, primarily from $40.6 million of net cash used in operating activities.

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 12, 2024
ODD, Research, NF2, RAF, RAS, Patient, Acquisition, Mesothelioma, Drug development, EHE, FDA, Food, Pharmaceutical industry

BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the fourth quarter and full year ending December 31, 2023. The Company also provided an update across the organization and pipeline.

Key Points: 
  • Closed 2023 in a strong financial position with $175M; runway into 2H 2026
    BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the fourth quarter and full year ending December 31, 2023.
  • Collaboration revenue for the three and twelve months ended December 31, 2023 was $0.7 million and $9.2 million, respectively.
  • Research and development expenses for the three and twelve months ended December 31, 2023 were $14.3 million and $59.7 million, respectively.
  • General and administrative for the three and twelve months ended December 31, 2023 were $8.3 million and $24.9 million, respectively.

South Carolina Jury Returns $1.75 Million Judgment in Workplace Mesothelioma Death

Retrieved on: 
Tuesday, March 26, 2024
Packaging, Legal, Professional Services, Manufacturing, South Carolina Supreme Court, Celanese, Supreme court, Mesothelioma, Courtroom View Network, Family, Workplace, Lawyer, Face, Asbestos, Cancer, Honeywell

Simon Greenstone Panatier trial lawyers secured a $1.75 million jury verdict for the family of a South Carolina maintenance worker who died from mesothelioma, a cancer caused by asbestos exposure at his workplace.

Key Points: 
  • Simon Greenstone Panatier trial lawyers secured a $1.75 million jury verdict for the family of a South Carolina maintenance worker who died from mesothelioma, a cancer caused by asbestos exposure at his workplace.
  • Curtis Wayne Bolton was responsible for replacing gaskets and packing on valves, pumps and other equipment at the Spartanburg, S.C.-area Celanese factory throughout the 1970s.
  • He was also exposed to amosite asbestos from insulation that he had to remove to access equipment at the plant, including flanges and valve and pump stems.
  • The case is Bolton v. Honeywell International et al., case number 2021CP4202480, in the 7th Judicial Circuit of South Carolina, and was heard by former South Carolina Supreme Court Chief Justice Jean Toal on a special asbestos docket.

Dean Omar Branham Shirley LLP Attorneys Named to 2024 Texas Rising Stars

Retrieved on: 
Thursday, March 21, 2024
Legal, Professional Services, Patent, HBO, Mesothelioma, Thomson Reuters, Research, Lawyer, Feedback, HBO Max, Film industry

Dean Omar Branham Shirley LLP is pleased to announce the selection of attorneys Rachel A.

Key Points: 
  • Dean Omar Branham Shirley LLP is pleased to announce the selection of attorneys Rachel A.
  • Gross and Sam Iola to the list of Texas Rising Stars for 2024, as published by Thomson Reuters.
  • The list recognizes Texas attorneys who are age 40 or below or have been in practice for 10 years or less.
  • Mr. Iola’s work on traumatic personal injury cases has led to Texas Rising Stars recognition each of the last seven years.

Adcendo ApS to Present Data on its Novel ADC Target uPARAP in Glioblastoma Multiforme at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Thursday, April 4, 2024
Research, Glioblastoma, Patient, GBM, Tumor microenvironment, University, Spacecraft, Abstract (summary), Biology, Mesothelioma, AACR, PDX, Cancer, University of Copenhagen, Poster, Finsen Laboratory, GIST, ADC, Invasion, Receptor (biochemistry), Associate professor

The data has been evaluated in collaboration with the Finsen Laboratory, Rigshospitalet/BRIC, University of Copenhagen, Copenhagen, Denmark.

Key Points: 
  • The data has been evaluated in collaboration with the Finsen Laboratory, Rigshospitalet/BRIC, University of Copenhagen, Copenhagen, Denmark.
  • uPARAP is a novel ADC target overexpressed by mesenchymal cancer cells including soft tissue and bone sarcomas, GIST as well as mesothelioma and glioblastoma, and has the potential to play a key role in modulating the tumor microenvironment.
  • The data demonstrate that uPARAP is strongly over-expressed in glioblastoma cells and that a uPARAP targeting ADC exhibits strong in vivo anti-tumor activity in a glioblastoma PDX model.
  • We are extremely encouraged by the data highlighted in this study, which provides further evidence on the potential effectiveness of uPARAP as a novel target for ADCs in glioblastoma multiforme.

Adcendo ApS to Present Data on its Novel ADC Target uPARAP in Glioblastoma Multiforme at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Thursday, April 4, 2024
Research, Glioblastoma, Patient, GBM, Tumor microenvironment, University, Spacecraft, Abstract (summary), Biology, Mesothelioma, AACR, PDX, Cancer, University of Copenhagen, Poster, Finsen Laboratory, GIST, ADC, Invasion, Receptor (biochemistry), Associate professor

The data has been evaluated in collaboration with the Finsen Laboratory, Rigshospitalet/BRIC, University of Copenhagen, Copenhagen, Denmark.

Key Points: 
  • The data has been evaluated in collaboration with the Finsen Laboratory, Rigshospitalet/BRIC, University of Copenhagen, Copenhagen, Denmark.
  • uPARAP is a novel ADC target overexpressed by mesenchymal cancer cells including soft tissue and bone sarcomas, GIST as well as mesothelioma and glioblastoma, and has the potential to play a key role in modulating the tumor microenvironment.
  • The data demonstrate that uPARAP is strongly over-expressed in glioblastoma cells and that a uPARAP targeting ADC exhibits strong in vivo anti-tumor activity in a glioblastoma PDX model.
  • We are extremely encouraged by the data highlighted in this study, which provides further evidence on the potential effectiveness of uPARAP as a novel target for ADCs in glioblastoma multiforme.

Rare Cancer Survivor Joins Experts at The Mesothelioma Center in TV Special on The Balancing Act Airing on Lifetime

Retrieved on: 
Tuesday, March 19, 2024
Diagnosis, RN, Disease, Lifetime (TV network), Patient, The Balancing Act, Mesothelioma, Survivor, Advocacy, Asbestos-related diseases, Balancing Act, Glomus tumor, Balancing

ORLANDO, Fla., March 19, 2024 /PRNewswire/ -- The Mesothelioma Center at Asbestos.com, the nation's most trusted resource for mesothelioma survivors and people diagnosed with other asbestos-related diseases, recently partnered with The Balancing Act on Lifetime TV. The program sheds light on mesothelioma and the many ways patients can seek support from Asbestos.com. The unique segment aired on March 18, 2024 and featured mesothelioma survivor Kim Madril, surgical oncologist Dr. Jacques Fontaine and Asbestos.com Patient Advocate Karen Selby, RN.

Key Points: 
  • The Mesothelioma Center at Asbestos.com has partnered with the national, award-winning morning show The Balancing Act to produce "Behind the Mystery: Mesothelioma."
  • ORLANDO, Fla., March 19, 2024 /PRNewswire/ -- The Mesothelioma Center at Asbestos.com , the nation's most trusted resource for mesothelioma survivors and people diagnosed with other asbestos-related diseases, recently partnered with The Balancing Act on Lifetime TV.
  • The program sheds light on mesothelioma and the many ways patients can seek support from Asbestos.com.
  • Mesothelioma survivor Kim Madril shared her experience with this disease, walking viewers through her initial symptoms, diagnosis and journey with The Mesothelioma Center.